To watch this as a video Download it and play it from the Downloads section in the Castbox app on your device.
In the very turbulent first year of this decade AZITHROMYCIN®, a 40-year-old drug, has almost become a household name being the subject of over 66,000 news media articles.
Is it being unfairly demonized because it's a cheap, effective drug competing with big pharma's patented +$2000 drug, Remdesivir? Does it deserve a place in the antifragile Biohacker's anti-COVID tool chest?
More about AZITHROMYCIN 📑 everything mentioned here
https://www.limitlessmindset.com/nootropics/1705-azithromycin
Order from RUPharma 🛒 #PayWithCrypto https://www.limitlessmindset.com/AZITHROMYCIN
Confused?
If you invest at least $150 in your Biohacking via LimitlessMindset.com, I will include a 30-minute free Biohacking consulting call with you. See my recommended Nootropics sources and Biohacking products here:
https://www.limitlessmindset.com/membership/secret-society
Forward a receipt of at least $150 to Consultations@LimitlessMindset.com
Join the Limitless Mindset email newsletter
https://www.limitlessmindset.com/membership/community-membership
Support My Work
My books
https://www.limitlessmindset.com/jr-books
Donate cryptocurrency
https://www.limitlessmindset.com/support#cryptocurrency
Connect with Jonathan
on Facebook
https://www.facebook.com/limitlessmindset
on Twitter
on Instagram
https://www.instagram.com/roselandjonathan/
on Gab
on Minds
https://www.minds.com/jroseland
on LBRY
on Telegram
I'm not a doctor, medical professional, or trained therapist. I'm a researcher and pragmatic biohacking practitioner exercising free speech to share evidence as I find it. I make no claims. Please practice skepticism and rational critical thinking. You should consult a professional about any serious decisions that you might make about your health. Affiliate links in this article support Limitless Mindset - spend over $100 and you'll be eligible to join the Limitless Mindset Secret Society.
Limitless Mindset (Videos) näytetään tässä palvelussa avoimen RSS-syötteen kautta. RSS-syötteen tiedostot, kuvaukset, kansikuvat ja muu metadata ovat podcastin omistajan omaisuutta, eivätkä ole yhteydessä Podplayn kanssa.